<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01360372</url>
  </required_header>
  <id_info>
    <org_study_id>Drexel18538</org_study_id>
    <nct_id>NCT01360372</nct_id>
  </id_info>
  <brief_title>Effect of Methylnaltrexone (Relistor) on Digestion and Tolerance to Tube Feeding in Patients Treated With Opiates</brief_title>
  <official_title>The Effect Of Methylnaltrexone (Relistorâ„¢) on Gut Motility and Tolerance to Tube Feeding in Patients Treated With Opiate Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drexel University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Drexel University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is hypothesized that using methylnaltrexone in addition to pain killer narcotics (opiates)
      in patients will result in increased tube feeding rates with more frequent nutrition at goal
      calorie rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tube feeding rates and tube feeding residual volumes will be measured and followed blinded to
      the treatment arm (methylnaltrexone vs. placebo) to evaluate if patients (who prior to study
      entry did not tolerate goal rates tube feeds) can get closer to tube feeding goal with the
      treatment arm.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No eligible subjects identified
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hydrogen breath test measure of bowel transit</measure>
    <time_frame>2 days</time_frame>
    <description>On day 1 Hydrogen Breath Test (HBT) measures will occur 30 minutes before test meal, immediately after test meal every 15 minutes until a rise of 5ppm is detected or until 4 hours have passed. On day 2 Hydrogen Breath test measures will occur 30 minutes before test meal, immediately after test meal and every 15 minutes until a rise of 5ppm is detected or until 4 hours have passed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastric residual volume measurement</measure>
    <time_frame>3 days</time_frame>
    <description>Gastric residual volumes will be measured at baseline study entry and then every 4 hours throughout the study until 24 hours post study drug administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Tube Feeding</condition>
  <arm_group>
    <arm_group_label>Methylnaltrexone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>saline placebo injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylnaltrexone</intervention_name>
    <description>Methylnaltrexone 8 mg IV for subjects 38 to 62 kg body weight, Methylnaltrexone12 mg IV for subjects 62.1 to 114 kg body weight</description>
    <arm_group_label>Methylnaltrexone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline injection</intervention_name>
    <description>Saline 0.4 to 0.8 ml injection</description>
    <arm_group_label>saline placebo injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inadequate tube feeding rate of greater than equal to 40% below goal rate.

          -  Prescribed opiate therapy for pain or sedation, stable dose for minimum 48 hours

          -  Stable dose or no dose laxative for minimum 72 hours

        Exclusion Criteria:

          -  Unstable Hemodynamics (eg. vasopressor medication)

          -  Pregnancy

          -  End stage Renal Disease on Dialysis

          -  Plan to wean opiates in next 48 hours

          -  Known or suspected mechanical gastrointestinal obstruction

          -  Initial expired hydrogen breath level greater than 20
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hahnemann University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Center of America</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2011</study_first_submitted>
  <study_first_submitted_qc>May 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2011</study_first_posted>
  <last_update_submitted>March 10, 2015</last_update_submitted>
  <last_update_submitted_qc>March 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Drexel University</investigator_affiliation>
    <investigator_full_name>Michael Sherman</investigator_full_name>
    <investigator_title>MD PI</investigator_title>
  </responsible_party>
  <keyword>Hydrogen breath test value and gastric residual volume measurements</keyword>
  <keyword>Tube feeding tolerance while taking a stable dose of opiate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opiate Alkaloids</mesh_term>
    <mesh_term>Methylnaltrexone</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

